IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.
Sonja Bendig, Alina M Hartmann, Wiebke Wessels, Thomas Beder, Rathana Kim, Marie Passet, Qingsong Gao, Nadine Wolgast, Johanna M Horns, Leonardo Alves Santos, Katharina Iben, Fabio D Steffen, Loredana Cantoni, Britta Kehden, Guranda Chitadze, Axel Künstner, Hauke Busch, Beat Bornhauser, Jean-Pierre Bourquin, Thibaut Tl Leguay, Nicolas Boissel, Nicola Gökbuget, Ilaria Iacobucci, Charles G Mullighan, Emmanuelle Clappier, Claudia D Baldus, Monika Brüggemann, Lorenz Bastian
Abstract
Large scale sequencing efforts have defined up to 27 diagnostic entities in B-ALL, leaving few samples without subtype assignment. Extended genomic and transcriptomic profiling in routine diagnostics broadens the sample collection and holds the potential to identify novel B-ALL subtypes. By analyzing an aggregated set of 4,857 B-ALL patients from three cohorts, we identified a novel group of twenty cases (age 18-66 years, median: 34 years) characterized by a previously undescribed IGH::FENDRR rearrangement exclusive to this subtype (n=17/20), KRAS p.A146T/V/P mutations (n=17/20 vs. n=86/4,857; p<0.001) and distinct DNA-methylation/gene expression profiles, including overexpression of the lncRNA FENDRR and the transcription factor FOXF1 ('FOXF1/FENDRR') as well as JAK/STAT and RAS signaling signatures. A gene expression machine learning classifier identified FOXF1/FENDRR cases in two independent cohorts with high accuracy. Patients treated according to GMALL/GRAALL protocols showed very poor chemotherapy response with n=8/13 having induction failure or MRD ≥10-3 and n=8/12 remaining MRD positive after 1st consolidation / salvage. MRD-stratified intensification including blinatumomab (n=10) and/or allogenic stem cell transplantation (n=12) resulted in ongoing molecular remission in 13/16 cases. FOXF1/FENDRR patients represent a novel B-ALL subtype which might benefit from early immunotherapeutic treatment or targeted interventions.